Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates.
Giansanti F, Capone E, Ponziani S, Piccolo E, Gentile R, Lamolinara A, Di Campli A, Sallese M, Iacobelli V, Cimini A, De Laurenzi V, Lattanzio R, Piantelli M, Ippoliti R, Sala G, Iacobelli S. Giansanti F, et al. Among authors: de laurenzi v. J Control Release. 2019 Jan 28;294:176-184. doi: 10.1016/j.jconrel.2018.12.018. Epub 2018 Dec 13. J Control Release. 2019. PMID: 30553852 Free article.
Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma.
Capone E, Lamolinara A, Pastorino F, Gentile R, Ponziani S, Di Vittorio G, D'Agostino D, Bibbò S, Rossi C, Piccolo E, Iacobelli V, Lattanzio R, Panella V, Sallese M, De Laurenzi V, Giansanti F, Sala A, Iezzi M, Ponzoni M, Ippoliti R, Iacobelli S, Sala G. Capone E, et al. Among authors: de laurenzi v. Cancers (Basel). 2020 Oct 15;12(10):2989. doi: 10.3390/cancers12102989. Cancers (Basel). 2020. PMID: 33076448 Free PMC article.
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.
Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, Lamolinara A, Mirza H, Barcaroli D, Ermler S, Silva E, Yasaei H, Newbold RF, Vagnarelli P, Mottolese M, Natali PG, Perracchio L, Quist J, Grigoriadis A, Marra P, Tutt AN, Piantelli M, Iacobelli S, De Laurenzi V, Sala A. Corda G, et al. Among authors: de laurenzi v. J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29. J Pathol. 2017. PMID: 27859262 Free PMC article.
ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, Chiorino G, Akkaya BG, Linton KJ, De Laurenzi V, Sala G, Falasca M. Adamska A, et al. Among authors: de laurenzi v. Adv Biol Regul. 2019 Aug;73:100634. doi: 10.1016/j.jbior.2019.04.004. Epub 2019 Apr 24. Adv Biol Regul. 2019. PMID: 31053501
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR, Capone E, Barcaroli D, D'Agostino D, Volpe S, Benfante A, van Hooff S, Iacobelli V, Rossi C, Iacobelli S, Medema JP, De Laurenzi V, Sala G. Prasetyanti PR, et al. Among authors: de laurenzi v. Oncotarget. 2015 Jul 10;6(19):16902-11. doi: 10.18632/oncotarget.4642. Oncotarget. 2015. PMID: 26160848 Free PMC article.
Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.
Basile A, De Marco M, Festa M, Falco A, Iorio V, Guerriero L, Eletto D, Rea D, Arra C, Lamolinara A, Ballerini P, Damiani V, Rosati A, Sala G, Turco MC, Marzullo L, De Laurenzi V. Basile A, et al. Among authors: de marco m, de laurenzi v. Mol Oncol. 2019 Jun;13(6):1388-1399. doi: 10.1002/1878-0261.12492. Epub 2019 May 17. Mol Oncol. 2019. PMID: 30973679 Free PMC article.
153 results